nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—CYP3A5—Temsirolimus—kidney cancer	0.0961	0.12	CbGbCtD
Halofantrine—KCNH2—Sunitinib—kidney cancer	0.0619	0.0774	CbGbCtD
Halofantrine—CYP2D6—Temsirolimus—kidney cancer	0.0589	0.0737	CbGbCtD
Halofantrine—CYP3A4—Everolimus—kidney cancer	0.0555	0.0694	CbGbCtD
Halofantrine—CYP2C8—Pazopanib—kidney cancer	0.0486	0.0607	CbGbCtD
Halofantrine—CYP3A4—Temsirolimus—kidney cancer	0.0375	0.0469	CbGbCtD
Halofantrine—CYP3A5—Erlotinib—kidney cancer	0.036	0.0451	CbGbCtD
Halofantrine—CYP2C8—Erlotinib—kidney cancer	0.0346	0.0433	CbGbCtD
Halofantrine—CYP3A5—Paclitaxel—kidney cancer	0.033	0.0412	CbGbCtD
Halofantrine—CYP2C8—Paclitaxel—kidney cancer	0.0317	0.0397	CbGbCtD
Halofantrine—CYP2D6—Pazopanib—kidney cancer	0.031	0.0387	CbGbCtD
Halofantrine—CYP3A5—Sorafenib—kidney cancer	0.0293	0.0366	CbGbCtD
Halofantrine—CYP3A5—Vincristine—kidney cancer	0.0284	0.0356	CbGbCtD
Halofantrine—CYP2C8—Sorafenib—kidney cancer	0.0282	0.0352	CbGbCtD
Halofantrine—CYP3A5—Sunitinib—kidney cancer	0.0237	0.0297	CbGbCtD
Halofantrine—CYP2D6—Erlotinib—kidney cancer	0.0221	0.0276	CbGbCtD
Halofantrine—CYP3A4—Pazopanib—kidney cancer	0.0197	0.0246	CbGbCtD
Halofantrine—CYP2D6—Sorafenib—kidney cancer	0.018	0.0225	CbGbCtD
Halofantrine—CYP2D6—Vinblastine—kidney cancer	0.0177	0.0222	CbGbCtD
Halofantrine—CYP3A4—Erlotinib—kidney cancer	0.0141	0.0176	CbGbCtD
Halofantrine—CYP3A4—Paclitaxel—kidney cancer	0.0129	0.0161	CbGbCtD
Halofantrine—CYP3A4—Sorafenib—kidney cancer	0.0114	0.0143	CbGbCtD
Halofantrine—CYP3A4—Vinblastine—kidney cancer	0.0113	0.0141	CbGbCtD
Halofantrine—CYP3A4—Vincristine—kidney cancer	0.0111	0.0139	CbGbCtD
Halofantrine—CYP2D6—Doxorubicin—kidney cancer	0.0109	0.0136	CbGbCtD
Halofantrine—CYP3A4—Sunitinib—kidney cancer	0.00926	0.0116	CbGbCtD
Halofantrine—CYP3A4—Doxorubicin—kidney cancer	0.00693	0.00867	CbGbCtD
Halofantrine—Back pain—Vincristine—kidney cancer	0.000435	0.00219	CcSEcCtD
Halofantrine—Fatigue—Erlotinib—kidney cancer	0.000432	0.00218	CcSEcCtD
Halofantrine—Anorexia—Sorafenib—kidney cancer	0.00043	0.00216	CcSEcCtD
Halofantrine—Feeling abnormal—Vinblastine—kidney cancer	0.00043	0.00216	CcSEcCtD
Halofantrine—Constipation—Erlotinib—kidney cancer	0.000428	0.00216	CcSEcCtD
Halofantrine—Myalgia—Dactinomycin—kidney cancer	0.000428	0.00216	CcSEcCtD
Halofantrine—Feeling abnormal—Everolimus—kidney cancer	0.000428	0.00216	CcSEcCtD
Halofantrine—Gastrointestinal pain—Vinblastine—kidney cancer	0.000426	0.00215	CcSEcCtD
Halofantrine—Gastrointestinal pain—Everolimus—kidney cancer	0.000425	0.00214	CcSEcCtD
Halofantrine—Abdominal distension—Capecitabine—kidney cancer	0.000423	0.00213	CcSEcCtD
Halofantrine—Discomfort—Dactinomycin—kidney cancer	0.000423	0.00213	CcSEcCtD
Halofantrine—Vomiting—Pazopanib—kidney cancer	0.000418	0.00211	CcSEcCtD
Halofantrine—Rash—Pazopanib—kidney cancer	0.000415	0.00209	CcSEcCtD
Halofantrine—Nausea—Temsirolimus—kidney cancer	0.000415	0.00209	CcSEcCtD
Halofantrine—Dermatitis—Pazopanib—kidney cancer	0.000414	0.00209	CcSEcCtD
Halofantrine—Anorexia—Sunitinib—kidney cancer	0.000413	0.00208	CcSEcCtD
Halofantrine—Back pain—Gemcitabine—kidney cancer	0.000412	0.00208	CcSEcCtD
Halofantrine—Abdominal pain—Vinblastine—kidney cancer	0.000412	0.00208	CcSEcCtD
Halofantrine—Headache—Pazopanib—kidney cancer	0.000412	0.00208	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000411	0.00207	CcSEcCtD
Halofantrine—Abdominal pain—Everolimus—kidney cancer	0.00041	0.00207	CcSEcCtD
Halofantrine—Gastrointestinal pain—Erlotinib—kidney cancer	0.00041	0.00206	CcSEcCtD
Halofantrine—Dyspepsia—Sorafenib—kidney cancer	0.000397	0.002	CcSEcCtD
Halofantrine—Abdominal pain—Erlotinib—kidney cancer	0.000396	0.002	CcSEcCtD
Halofantrine—Ill-defined disorder—Gemcitabine—kidney cancer	0.000396	0.00199	CcSEcCtD
Halofantrine—Visual impairment—Paclitaxel—kidney cancer	0.000395	0.00199	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000395	0.00199	CcSEcCtD
Halofantrine—Decreased appetite—Sorafenib—kidney cancer	0.000392	0.00197	CcSEcCtD
Halofantrine—Anorexia—Dactinomycin—kidney cancer	0.000391	0.00197	CcSEcCtD
Halofantrine—Nausea—Pazopanib—kidney cancer	0.000391	0.00197	CcSEcCtD
Halofantrine—Paraesthesia—Sunitinib—kidney cancer	0.000389	0.00196	CcSEcCtD
Halofantrine—Convulsion—Vincristine—kidney cancer	0.000389	0.00196	CcSEcCtD
Halofantrine—Fatigue—Sorafenib—kidney cancer	0.000389	0.00196	CcSEcCtD
Halofantrine—Constipation—Sorafenib—kidney cancer	0.000385	0.00194	CcSEcCtD
Halofantrine—Malaise—Gemcitabine—kidney cancer	0.000384	0.00194	CcSEcCtD
Halofantrine—Pulmonary oedema—Doxorubicin—kidney cancer	0.000384	0.00194	CcSEcCtD
Halofantrine—Myalgia—Vincristine—kidney cancer	0.000383	0.00193	CcSEcCtD
Halofantrine—Tinnitus—Paclitaxel—kidney cancer	0.000382	0.00193	CcSEcCtD
Halofantrine—Dyspepsia—Sunitinib—kidney cancer	0.000382	0.00192	CcSEcCtD
Halofantrine—Decreased appetite—Sunitinib—kidney cancer	0.000377	0.0019	CcSEcCtD
Halofantrine—Abnormal vision—Doxorubicin—kidney cancer	0.000377	0.0019	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000374	0.00188	CcSEcCtD
Halofantrine—Asthenia—Vinblastine—kidney cancer	0.000374	0.00188	CcSEcCtD
Halofantrine—Fatigue—Sunitinib—kidney cancer	0.000374	0.00188	CcSEcCtD
Halofantrine—Asthenia—Everolimus—kidney cancer	0.000373	0.00188	CcSEcCtD
Halofantrine—Cough—Gemcitabine—kidney cancer	0.000372	0.00187	CcSEcCtD
Halofantrine—Constipation—Sunitinib—kidney cancer	0.000371	0.00187	CcSEcCtD
Halofantrine—Gastrointestinal pain—Sorafenib—kidney cancer	0.000369	0.00186	CcSEcCtD
Halofantrine—Chills—Paclitaxel—kidney cancer	0.000368	0.00185	CcSEcCtD
Halofantrine—Pruritus—Everolimus—kidney cancer	0.000367	0.00185	CcSEcCtD
Halofantrine—Anaphylactic shock—Vincristine—kidney cancer	0.000367	0.00185	CcSEcCtD
Halofantrine—Arrhythmia—Paclitaxel—kidney cancer	0.000366	0.00185	CcSEcCtD
Halofantrine—Stomatitis—Capecitabine—kidney cancer	0.000365	0.00184	CcSEcCtD
Halofantrine—Myalgia—Gemcitabine—kidney cancer	0.000363	0.00183	CcSEcCtD
Halofantrine—Chest pain—Gemcitabine—kidney cancer	0.000363	0.00183	CcSEcCtD
Halofantrine—Arthralgia—Gemcitabine—kidney cancer	0.000363	0.00183	CcSEcCtD
Halofantrine—Asthenia—Erlotinib—kidney cancer	0.000359	0.00181	CcSEcCtD
Halofantrine—Discomfort—Gemcitabine—kidney cancer	0.000359	0.00181	CcSEcCtD
Halofantrine—Urticaria—Sorafenib—kidney cancer	0.000358	0.0018	CcSEcCtD
Halofantrine—Decreased appetite—Dactinomycin—kidney cancer	0.000357	0.0018	CcSEcCtD
Halofantrine—Diarrhoea—Vinblastine—kidney cancer	0.000357	0.0018	CcSEcCtD
Halofantrine—Abdominal pain—Sorafenib—kidney cancer	0.000356	0.0018	CcSEcCtD
Halofantrine—Diarrhoea—Everolimus—kidney cancer	0.000355	0.00179	CcSEcCtD
Halofantrine—Gastrointestinal pain—Sunitinib—kidney cancer	0.000355	0.00179	CcSEcCtD
Halofantrine—Pruritus—Erlotinib—kidney cancer	0.000354	0.00179	CcSEcCtD
Halofantrine—Fatigue—Dactinomycin—kidney cancer	0.000354	0.00178	CcSEcCtD
Halofantrine—Anorexia—Vincristine—kidney cancer	0.00035	0.00176	CcSEcCtD
Halofantrine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000348	0.00175	CcSEcCtD
Halofantrine—Back pain—Paclitaxel—kidney cancer	0.000345	0.00174	CcSEcCtD
Halofantrine—Dizziness—Vinblastine—kidney cancer	0.000345	0.00174	CcSEcCtD
Halofantrine—Dizziness—Everolimus—kidney cancer	0.000343	0.00173	CcSEcCtD
Halofantrine—Abdominal pain—Sunitinib—kidney cancer	0.000343	0.00173	CcSEcCtD
Halofantrine—Diarrhoea—Erlotinib—kidney cancer	0.000343	0.00173	CcSEcCtD
Halofantrine—Feeling abnormal—Dactinomycin—kidney cancer	0.000338	0.0017	CcSEcCtD
Halofantrine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000336	0.00169	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000334	0.00168	CcSEcCtD
Halofantrine—Anorexia—Gemcitabine—kidney cancer	0.000332	0.00167	CcSEcCtD
Halofantrine—Vomiting—Vinblastine—kidney cancer	0.000331	0.00167	CcSEcCtD
Halofantrine—Dizziness—Erlotinib—kidney cancer	0.000331	0.00167	CcSEcCtD
Halofantrine—Ill-defined disorder—Paclitaxel—kidney cancer	0.000331	0.00167	CcSEcCtD
Halofantrine—Vomiting—Everolimus—kidney cancer	0.00033	0.00166	CcSEcCtD
Halofantrine—Paraesthesia—Vincristine—kidney cancer	0.000329	0.00166	CcSEcCtD
Halofantrine—Rash—Everolimus—kidney cancer	0.000327	0.00165	CcSEcCtD
Halofantrine—Dermatitis—Everolimus—kidney cancer	0.000327	0.00165	CcSEcCtD
Halofantrine—Headache—Vinblastine—kidney cancer	0.000327	0.00165	CcSEcCtD
Halofantrine—Headache—Everolimus—kidney cancer	0.000325	0.00164	CcSEcCtD
Halofantrine—Abdominal pain—Dactinomycin—kidney cancer	0.000325	0.00164	CcSEcCtD
Halofantrine—Visual impairment—Capecitabine—kidney cancer	0.000324	0.00163	CcSEcCtD
Halofantrine—Asthenia—Sorafenib—kidney cancer	0.000323	0.00163	CcSEcCtD
Halofantrine—Malaise—Paclitaxel—kidney cancer	0.000322	0.00162	CcSEcCtD
Halofantrine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.00032	0.00161	CcSEcCtD
Halofantrine—Decreased appetite—Vincristine—kidney cancer	0.000319	0.00161	CcSEcCtD
Halofantrine—Pruritus—Sorafenib—kidney cancer	0.000319	0.00161	CcSEcCtD
Halofantrine—Vomiting—Erlotinib—kidney cancer	0.000319	0.0016	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000317	0.0016	CcSEcCtD
Halofantrine—Fatigue—Vincristine—kidney cancer	0.000316	0.00159	CcSEcCtD
Halofantrine—Rash—Erlotinib—kidney cancer	0.000316	0.00159	CcSEcCtD
Halofantrine—Dermatitis—Erlotinib—kidney cancer	0.000316	0.00159	CcSEcCtD
Halofantrine—Palpitations—Paclitaxel—kidney cancer	0.000315	0.00159	CcSEcCtD
Halofantrine—Headache—Erlotinib—kidney cancer	0.000314	0.00158	CcSEcCtD
Halofantrine—Tinnitus—Capecitabine—kidney cancer	0.000314	0.00158	CcSEcCtD
Halofantrine—Constipation—Vincristine—kidney cancer	0.000314	0.00158	CcSEcCtD
Halofantrine—Paraesthesia—Gemcitabine—kidney cancer	0.000312	0.00157	CcSEcCtD
Halofantrine—Cough—Paclitaxel—kidney cancer	0.000312	0.00157	CcSEcCtD
Halofantrine—Asthenia—Sunitinib—kidney cancer	0.000311	0.00157	CcSEcCtD
Halofantrine—Nausea—Vinblastine—kidney cancer	0.00031	0.00156	CcSEcCtD
Halofantrine—Convulsion—Paclitaxel—kidney cancer	0.000309	0.00156	CcSEcCtD
Halofantrine—Nausea—Everolimus—kidney cancer	0.000308	0.00155	CcSEcCtD
Halofantrine—Diarrhoea—Sorafenib—kidney cancer	0.000308	0.00155	CcSEcCtD
Halofantrine—Pruritus—Sunitinib—kidney cancer	0.000307	0.00155	CcSEcCtD
Halofantrine—Arthralgia—Paclitaxel—kidney cancer	0.000304	0.00153	CcSEcCtD
Halofantrine—Chest pain—Paclitaxel—kidney cancer	0.000304	0.00153	CcSEcCtD
Halofantrine—Myalgia—Paclitaxel—kidney cancer	0.000304	0.00153	CcSEcCtD
Halofantrine—Face oedema—Doxorubicin—kidney cancer	0.000303	0.00153	CcSEcCtD
Halofantrine—Decreased appetite—Gemcitabine—kidney cancer	0.000302	0.00152	CcSEcCtD
Halofantrine—Chills—Capecitabine—kidney cancer	0.000302	0.00152	CcSEcCtD
Halofantrine—Arrhythmia—Capecitabine—kidney cancer	0.000301	0.00151	CcSEcCtD
Halofantrine—Discomfort—Paclitaxel—kidney cancer	0.0003	0.00151	CcSEcCtD
Halofantrine—Fatigue—Gemcitabine—kidney cancer	0.0003	0.00151	CcSEcCtD
Halofantrine—Gastrointestinal pain—Vincristine—kidney cancer	0.0003	0.00151	CcSEcCtD
Halofantrine—Dizziness—Sorafenib—kidney cancer	0.000298	0.0015	CcSEcCtD
Halofantrine—Constipation—Gemcitabine—kidney cancer	0.000298	0.0015	CcSEcCtD
Halofantrine—Nausea—Erlotinib—kidney cancer	0.000298	0.0015	CcSEcCtD
Halofantrine—Diarrhoea—Sunitinib—kidney cancer	0.000297	0.0015	CcSEcCtD
Halofantrine—Asthenia—Dactinomycin—kidney cancer	0.000295	0.00148	CcSEcCtD
Halofantrine—Confusional state—Paclitaxel—kidney cancer	0.000294	0.00148	CcSEcCtD
Halofantrine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000291	0.00147	CcSEcCtD
Halofantrine—Abdominal pain—Vincristine—kidney cancer	0.00029	0.00146	CcSEcCtD
Halofantrine—Dizziness—Sunitinib—kidney cancer	0.000287	0.00145	CcSEcCtD
Halofantrine—Feeling abnormal—Gemcitabine—kidney cancer	0.000287	0.00144	CcSEcCtD
Halofantrine—Vomiting—Sorafenib—kidney cancer	0.000287	0.00144	CcSEcCtD
Halofantrine—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000286	0.00144	CcSEcCtD
Halofantrine—Rash—Sorafenib—kidney cancer	0.000284	0.00143	CcSEcCtD
Halofantrine—Dermatitis—Sorafenib—kidney cancer	0.000284	0.00143	CcSEcCtD
Halofantrine—Back pain—Capecitabine—kidney cancer	0.000283	0.00143	CcSEcCtD
Halofantrine—Headache—Sorafenib—kidney cancer	0.000282	0.00142	CcSEcCtD
Halofantrine—Diarrhoea—Dactinomycin—kidney cancer	0.000281	0.00142	CcSEcCtD
Halofantrine—Anorexia—Paclitaxel—kidney cancer	0.000278	0.0014	CcSEcCtD
Halofantrine—Vomiting—Sunitinib—kidney cancer	0.000276	0.00139	CcSEcCtD
Halofantrine—Rash—Sunitinib—kidney cancer	0.000273	0.00138	CcSEcCtD
Halofantrine—Dermatitis—Sunitinib—kidney cancer	0.000273	0.00138	CcSEcCtD
Halofantrine—Abdominal distension—Doxorubicin—kidney cancer	0.000273	0.00137	CcSEcCtD
Halofantrine—Ill-defined disorder—Capecitabine—kidney cancer	0.000272	0.00137	CcSEcCtD
Halofantrine—Headache—Sunitinib—kidney cancer	0.000272	0.00137	CcSEcCtD
Halofantrine—Nausea—Sorafenib—kidney cancer	0.000268	0.00135	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000265	0.00134	CcSEcCtD
Halofantrine—Malaise—Capecitabine—kidney cancer	0.000264	0.00133	CcSEcCtD
Halofantrine—Asthenia—Vincristine—kidney cancer	0.000263	0.00133	CcSEcCtD
Halofantrine—Paraesthesia—Paclitaxel—kidney cancer	0.000262	0.00132	CcSEcCtD
Halofantrine—Vomiting—Dactinomycin—kidney cancer	0.000261	0.00132	CcSEcCtD
Halofantrine—Palpitations—Capecitabine—kidney cancer	0.000259	0.0013	CcSEcCtD
Halofantrine—Rash—Dactinomycin—kidney cancer	0.000259	0.0013	CcSEcCtD
Halofantrine—Nausea—Sunitinib—kidney cancer	0.000258	0.0013	CcSEcCtD
Halofantrine—Dyspepsia—Paclitaxel—kidney cancer	0.000256	0.00129	CcSEcCtD
Halofantrine—Cough—Capecitabine—kidney cancer	0.000256	0.00129	CcSEcCtD
Halofantrine—Decreased appetite—Paclitaxel—kidney cancer	0.000253	0.00128	CcSEcCtD
Halofantrine—Fatigue—Paclitaxel—kidney cancer	0.000251	0.00127	CcSEcCtD
Halofantrine—Diarrhoea—Vincristine—kidney cancer	0.000251	0.00126	CcSEcCtD
Halofantrine—Pollakiuria—Doxorubicin—kidney cancer	0.00025	0.00126	CcSEcCtD
Halofantrine—Asthenia—Gemcitabine—kidney cancer	0.00025	0.00126	CcSEcCtD
Halofantrine—Arthralgia—Capecitabine—kidney cancer	0.000249	0.00126	CcSEcCtD
Halofantrine—Myalgia—Capecitabine—kidney cancer	0.000249	0.00126	CcSEcCtD
Halofantrine—Chest pain—Capecitabine—kidney cancer	0.000249	0.00126	CcSEcCtD
Halofantrine—Constipation—Paclitaxel—kidney cancer	0.000249	0.00126	CcSEcCtD
Halofantrine—Discomfort—Capecitabine—kidney cancer	0.000246	0.00124	CcSEcCtD
Halofantrine—Pruritus—Gemcitabine—kidney cancer	0.000246	0.00124	CcSEcCtD
Halofantrine—Nausea—Dactinomycin—kidney cancer	0.000244	0.00123	CcSEcCtD
Halofantrine—Dizziness—Vincristine—kidney cancer	0.000243	0.00122	CcSEcCtD
Halofantrine—Confusional state—Capecitabine—kidney cancer	0.000241	0.00121	CcSEcCtD
Halofantrine—Feeling abnormal—Paclitaxel—kidney cancer	0.00024	0.00121	CcSEcCtD
Halofantrine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000238	0.0012	CcSEcCtD
Halofantrine—Diarrhoea—Gemcitabine—kidney cancer	0.000238	0.0012	CcSEcCtD
Halofantrine—Stomatitis—Doxorubicin—kidney cancer	0.000236	0.00119	CcSEcCtD
Halofantrine—Vomiting—Vincristine—kidney cancer	0.000233	0.00118	CcSEcCtD
Halofantrine—Urticaria—Paclitaxel—kidney cancer	0.000231	0.00117	CcSEcCtD
Halofantrine—Rash—Vincristine—kidney cancer	0.000231	0.00117	CcSEcCtD
Halofantrine—Dermatitis—Vincristine—kidney cancer	0.000231	0.00116	CcSEcCtD
Halofantrine—Abdominal pain—Paclitaxel—kidney cancer	0.00023	0.00116	CcSEcCtD
Halofantrine—Headache—Vincristine—kidney cancer	0.00023	0.00116	CcSEcCtD
Halofantrine—Anorexia—Capecitabine—kidney cancer	0.000228	0.00115	CcSEcCtD
Halofantrine—Vomiting—Gemcitabine—kidney cancer	0.000221	0.00111	CcSEcCtD
Halofantrine—Rash—Gemcitabine—kidney cancer	0.000219	0.00111	CcSEcCtD
Halofantrine—Dermatitis—Gemcitabine—kidney cancer	0.000219	0.0011	CcSEcCtD
Halofantrine—Headache—Gemcitabine—kidney cancer	0.000218	0.0011	CcSEcCtD
Halofantrine—Nausea—Vincristine—kidney cancer	0.000218	0.0011	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000218	0.0011	CcSEcCtD
Halofantrine—Paraesthesia—Capecitabine—kidney cancer	0.000215	0.00108	CcSEcCtD
Halofantrine—Dyspepsia—Capecitabine—kidney cancer	0.00021	0.00106	CcSEcCtD
Halofantrine—Visual impairment—Doxorubicin—kidney cancer	0.000209	0.00105	CcSEcCtD
Halofantrine—Asthenia—Paclitaxel—kidney cancer	0.000209	0.00105	CcSEcCtD
Halofantrine—Decreased appetite—Capecitabine—kidney cancer	0.000208	0.00105	CcSEcCtD
Halofantrine—Nausea—Gemcitabine—kidney cancer	0.000207	0.00104	CcSEcCtD
Halofantrine—Fatigue—Capecitabine—kidney cancer	0.000206	0.00104	CcSEcCtD
Halofantrine—Pruritus—Paclitaxel—kidney cancer	0.000206	0.00104	CcSEcCtD
Halofantrine—Constipation—Capecitabine—kidney cancer	0.000204	0.00103	CcSEcCtD
Halofantrine—Tinnitus—Doxorubicin—kidney cancer	0.000202	0.00102	CcSEcCtD
Halofantrine—Diarrhoea—Paclitaxel—kidney cancer	0.000199	0.001	CcSEcCtD
Halofantrine—Feeling abnormal—Capecitabine—kidney cancer	0.000197	0.000993	CcSEcCtD
Halofantrine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000196	0.000985	CcSEcCtD
Halofantrine—Chills—Doxorubicin—kidney cancer	0.000195	0.000981	CcSEcCtD
Halofantrine—Arrhythmia—Doxorubicin—kidney cancer	0.000194	0.000976	CcSEcCtD
Halofantrine—Dizziness—Paclitaxel—kidney cancer	0.000193	0.000971	CcSEcCtD
Halofantrine—Urticaria—Capecitabine—kidney cancer	0.00019	0.000957	CcSEcCtD
Halofantrine—Abdominal pain—Capecitabine—kidney cancer	0.000189	0.000952	CcSEcCtD
Halofantrine—Vomiting—Paclitaxel—kidney cancer	0.000185	0.000933	CcSEcCtD
Halofantrine—Rash—Paclitaxel—kidney cancer	0.000184	0.000926	CcSEcCtD
Halofantrine—Dermatitis—Paclitaxel—kidney cancer	0.000184	0.000925	CcSEcCtD
Halofantrine—Back pain—Doxorubicin—kidney cancer	0.000183	0.00092	CcSEcCtD
Halofantrine—Headache—Paclitaxel—kidney cancer	0.000183	0.00092	CcSEcCtD
Halofantrine—Ill-defined disorder—Doxorubicin—kidney cancer	0.000175	0.000883	CcSEcCtD
Halofantrine—Nausea—Paclitaxel—kidney cancer	0.000173	0.000872	CcSEcCtD
Halofantrine—Asthenia—Capecitabine—kidney cancer	0.000172	0.000864	CcSEcCtD
Halofantrine—Malaise—Doxorubicin—kidney cancer	0.00017	0.000858	CcSEcCtD
Halofantrine—Pruritus—Capecitabine—kidney cancer	0.000169	0.000852	CcSEcCtD
Halofantrine—Palpitations—Doxorubicin—kidney cancer	0.000167	0.000841	CcSEcCtD
Halofantrine—Cough—Doxorubicin—kidney cancer	0.000165	0.00083	CcSEcCtD
Halofantrine—Convulsion—Doxorubicin—kidney cancer	0.000164	0.000824	CcSEcCtD
Halofantrine—Diarrhoea—Capecitabine—kidney cancer	0.000164	0.000824	CcSEcCtD
Halofantrine—Arthralgia—Doxorubicin—kidney cancer	0.000161	0.00081	CcSEcCtD
Halofantrine—Myalgia—Doxorubicin—kidney cancer	0.000161	0.00081	CcSEcCtD
Halofantrine—Chest pain—Doxorubicin—kidney cancer	0.000161	0.00081	CcSEcCtD
Halofantrine—Discomfort—Doxorubicin—kidney cancer	0.000159	0.0008	CcSEcCtD
Halofantrine—Dizziness—Capecitabine—kidney cancer	0.000158	0.000797	CcSEcCtD
Halofantrine—Confusional state—Doxorubicin—kidney cancer	0.000155	0.000783	CcSEcCtD
Halofantrine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000154	0.000777	CcSEcCtD
Halofantrine—Vomiting—Capecitabine—kidney cancer	0.000152	0.000766	CcSEcCtD
Halofantrine—Rash—Capecitabine—kidney cancer	0.000151	0.00076	CcSEcCtD
Halofantrine—Dermatitis—Capecitabine—kidney cancer	0.000151	0.000759	CcSEcCtD
Halofantrine—Headache—Capecitabine—kidney cancer	0.00015	0.000755	CcSEcCtD
Halofantrine—Anorexia—Doxorubicin—kidney cancer	0.000147	0.00074	CcSEcCtD
Halofantrine—Nausea—Capecitabine—kidney cancer	0.000142	0.000716	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.00014	0.000708	CcSEcCtD
Halofantrine—Paraesthesia—Doxorubicin—kidney cancer	0.000138	0.000697	CcSEcCtD
Halofantrine—Dyspepsia—Doxorubicin—kidney cancer	0.000136	0.000684	CcSEcCtD
Halofantrine—Decreased appetite—Doxorubicin—kidney cancer	0.000134	0.000675	CcSEcCtD
Halofantrine—Fatigue—Doxorubicin—kidney cancer	0.000133	0.00067	CcSEcCtD
Halofantrine—Constipation—Doxorubicin—kidney cancer	0.000132	0.000664	CcSEcCtD
Halofantrine—Feeling abnormal—Doxorubicin—kidney cancer	0.000127	0.00064	CcSEcCtD
Halofantrine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000126	0.000635	CcSEcCtD
Halofantrine—Urticaria—Doxorubicin—kidney cancer	0.000122	0.000617	CcSEcCtD
Halofantrine—Abdominal pain—Doxorubicin—kidney cancer	0.000122	0.000614	CcSEcCtD
Halofantrine—Asthenia—Doxorubicin—kidney cancer	0.000111	0.000557	CcSEcCtD
Halofantrine—Pruritus—Doxorubicin—kidney cancer	0.000109	0.000549	CcSEcCtD
Halofantrine—Diarrhoea—Doxorubicin—kidney cancer	0.000105	0.000531	CcSEcCtD
Halofantrine—Dizziness—Doxorubicin—kidney cancer	0.000102	0.000514	CcSEcCtD
Halofantrine—Vomiting—Doxorubicin—kidney cancer	9.8e-05	0.000494	CcSEcCtD
Halofantrine—Rash—Doxorubicin—kidney cancer	9.72e-05	0.00049	CcSEcCtD
Halofantrine—Dermatitis—Doxorubicin—kidney cancer	9.71e-05	0.000489	CcSEcCtD
Halofantrine—Headache—Doxorubicin—kidney cancer	9.65e-05	0.000486	CcSEcCtD
Halofantrine—Nausea—Doxorubicin—kidney cancer	9.15e-05	0.000461	CcSEcCtD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—HSPD1—kidney cancer	1.99e-05	0.0115	CbGpPWpGaD
Halofantrine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	1.97e-05	0.0114	CbGpPWpGaD
Halofantrine—CYP2C8—Tamoxifen metabolism—CYP1A1—kidney cancer	1.93e-05	0.0112	CbGpPWpGaD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	1.91e-05	0.011	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—ACY1—kidney cancer	1.85e-05	0.0107	CbGpPWpGaD
Halofantrine—CYP3A5—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	1.73e-05	0.01	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—IL13—kidney cancer	1.68e-05	0.00968	CbGpPWpGaD
Halofantrine—CYP2D6—Xenobiotics—CYP1A1—kidney cancer	1.65e-05	0.00954	CbGpPWpGaD
Halofantrine—CYP2D6—Tamoxifen metabolism—CYP1A1—kidney cancer	1.59e-05	0.00917	CbGpPWpGaD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	1.57e-05	0.00905	CbGpPWpGaD
Halofantrine—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	1.56e-05	0.00902	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—ACY1—kidney cancer	1.52e-05	0.00877	CbGpPWpGaD
Halofantrine—CYP2C8—Arachidonic acid metabolism—PTGS1—kidney cancer	1.5e-05	0.00866	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—KCNMA1—kidney cancer	1.4e-05	0.00807	CbGpPWpGaD
Halofantrine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	1.34e-05	0.00771	CbGpPWpGaD
Halofantrine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	1.29e-05	0.00745	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—EGR1—kidney cancer	1.27e-05	0.00733	CbGpPWpGaD
Halofantrine—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	1.24e-05	0.00715	CbGpPWpGaD
Halofantrine—CYP2D6—Melatonin metabolism and effects—CYP1A1—kidney cancer	1.23e-05	0.00708	CbGpPWpGaD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	1.21e-05	0.00701	CbGpPWpGaD
Halofantrine—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	1.17e-05	0.00678	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—ALDH1A1—kidney cancer	1.17e-05	0.00676	CbGpPWpGaD
Halofantrine—CYP3A4—Irinotecan Pathway—APC—kidney cancer	1.12e-05	0.0065	CbGpPWpGaD
Halofantrine—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	1.08e-05	0.00623	CbGpPWpGaD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	1.05e-05	0.00607	CbGpPWpGaD
Halofantrine—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	1.04e-05	0.006	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—ACHE—kidney cancer	1.03e-05	0.00597	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	1.02e-05	0.00591	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—ALDH1A1—kidney cancer	1.01e-05	0.00585	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—ACY1—kidney cancer	9.93e-06	0.00573	CbGpPWpGaD
Halofantrine—CYP2C8—Arachidonic acid metabolism—CYP1A1—kidney cancer	9.66e-06	0.00558	CbGpPWpGaD
Halofantrine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	9.64e-06	0.00557	CbGpPWpGaD
Halofantrine—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	9.51e-06	0.0055	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—BCHE—kidney cancer	9e-06	0.0052	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—HIF1A—kidney cancer	8.83e-06	0.0051	CbGpPWpGaD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	8.62e-06	0.00498	CbGpPWpGaD
Halofantrine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	8.35e-06	0.00482	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—ALDH1A1—kidney cancer	8.32e-06	0.00481	CbGpPWpGaD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	8.24e-06	0.00476	CbGpPWpGaD
Halofantrine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	8.05e-06	0.00465	CbGpPWpGaD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	7.81e-06	0.00451	CbGpPWpGaD
Halofantrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	7.67e-06	0.00443	CbGpPWpGaD
Halofantrine—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	7.19e-06	0.00415	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTT1—kidney cancer	6.87e-06	0.00397	CbGpPWpGaD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	6.85e-06	0.00396	CbGpPWpGaD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	6.77e-06	0.00391	CbGpPWpGaD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	6.76e-06	0.00391	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—PTGS1—kidney cancer	6.44e-06	0.00372	CbGpPWpGaD
Halofantrine—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	6.22e-06	0.0036	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTT1—kidney cancer	5.95e-06	0.00344	CbGpPWpGaD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.83e-06	0.00337	CbGpPWpGaD
Halofantrine—CYP2C8—Arachidonic acid metabolism—PTGS2—kidney cancer	5.74e-06	0.00332	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	5.64e-06	0.00326	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—PTGS1—kidney cancer	5.58e-06	0.00322	CbGpPWpGaD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	5.56e-06	0.00321	CbGpPWpGaD
Halofantrine—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	5.54e-06	0.0032	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	5.44e-06	0.00314	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—JUN—kidney cancer	5.33e-06	0.00308	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	5.29e-06	0.00305	CbGpPWpGaD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	5.11e-06	0.00295	CbGpPWpGaD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.05e-06	0.00292	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	4.92e-06	0.00284	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTT1—kidney cancer	4.89e-06	0.00282	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTP1—kidney cancer	4.76e-06	0.00275	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTP1—kidney cancer	4.7e-06	0.00271	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—VEGFA—kidney cancer	4.65e-06	0.00269	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—BRAF—kidney cancer	4.59e-06	0.00265	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—PTGS1—kidney cancer	4.58e-06	0.00265	CbGpPWpGaD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	4.48e-06	0.00259	CbGpPWpGaD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	4.42e-06	0.00255	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTM1—kidney cancer	4.38e-06	0.00253	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTM1—kidney cancer	4.32e-06	0.00249	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—CYP1A1—kidney cancer	4.15e-06	0.0024	CbGpPWpGaD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—kidney cancer	4.14e-06	0.00239	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTP1—kidney cancer	4.13e-06	0.00238	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP1A1—kidney cancer	4.09e-06	0.00236	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTP1—kidney cancer	4.07e-06	0.00235	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—RAF1—kidney cancer	3.84e-06	0.00222	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTM1—kidney cancer	3.79e-06	0.00219	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTM1—kidney cancer	3.74e-06	0.00216	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ACY1—kidney cancer	3.65e-06	0.00211	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	3.63e-06	0.0021	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—CYP1A1—kidney cancer	3.6e-06	0.00208	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP1A1—kidney cancer	3.55e-06	0.00205	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTP1—kidney cancer	3.39e-06	0.00196	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTP1—kidney cancer	3.34e-06	0.00193	CbGpPWpGaD
Halofantrine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	3.34e-06	0.00193	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTT1—kidney cancer	3.2e-06	0.00185	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ACY1—kidney cancer	3.16e-06	0.00183	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTM1—kidney cancer	3.11e-06	0.0018	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PDHB—kidney cancer	3.1e-06	0.00179	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—POMC—kidney cancer	3.09e-06	0.00179	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTM1—kidney cancer	3.07e-06	0.00177	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—PTGS1—kidney cancer	2.99e-06	0.00173	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—CYP1A1—kidney cancer	2.95e-06	0.00171	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CCBL1—kidney cancer	2.92e-06	0.00169	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP1A1—kidney cancer	2.91e-06	0.00168	CbGpPWpGaD
Halofantrine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	2.71e-06	0.00156	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.7e-06	0.00156	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PDHB—kidney cancer	2.69e-06	0.00155	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—POMC—kidney cancer	2.68e-06	0.00155	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—MAPK1—kidney cancer	2.63e-06	0.00152	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ACY1—kidney cancer	2.6e-06	0.0015	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PPAT—kidney cancer	2.53e-06	0.00146	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GLIPR1—kidney cancer	2.53e-06	0.00146	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CCBL1—kidney cancer	2.53e-06	0.00146	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—FH—kidney cancer	2.35e-06	0.00136	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—APRT—kidney cancer	2.35e-06	0.00136	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.29e-06	0.00132	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTP1—kidney cancer	2.22e-06	0.00128	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GPC3—kidney cancer	2.21e-06	0.00128	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PDHB—kidney cancer	2.21e-06	0.00128	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—POMC—kidney cancer	2.2e-06	0.00127	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GLIPR1—kidney cancer	2.19e-06	0.00127	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PPAT—kidney cancer	2.19e-06	0.00127	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	2.18e-06	0.00126	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.16e-06	0.00125	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CA2—kidney cancer	2.15e-06	0.00124	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.14e-06	0.00124	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ALAD—kidney cancer	2.1e-06	0.00121	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CCBL1—kidney cancer	2.08e-06	0.0012	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ST3GAL2—kidney cancer	2.05e-06	0.00118	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—APRT—kidney cancer	2.04e-06	0.00118	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—FH—kidney cancer	2.04e-06	0.00118	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.04e-06	0.00118	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.01e-06	0.00116	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ALDH1A1—kidney cancer	2e-06	0.00116	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.99e-06	0.00115	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	1.93e-06	0.00111	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PGK1—kidney cancer	1.92e-06	0.00111	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—SLC5A3—kidney cancer	1.92e-06	0.00111	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GPC3—kidney cancer	1.92e-06	0.00111	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	1.9e-06	0.0011	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—LDHB—kidney cancer	1.88e-06	0.00109	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CA2—kidney cancer	1.86e-06	0.00108	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ALAD—kidney cancer	1.82e-06	0.00105	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PPAT—kidney cancer	1.8e-06	0.00104	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GLIPR1—kidney cancer	1.8e-06	0.00104	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ST3GAL2—kidney cancer	1.77e-06	0.00102	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ALDH1A1—kidney cancer	1.73e-06	0.001	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ACY1—kidney cancer	1.7e-06	0.000981	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—APRT—kidney cancer	1.67e-06	0.000966	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—FH—kidney cancer	1.67e-06	0.000966	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PGK1—kidney cancer	1.66e-06	0.00096	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—SLC5A3—kidney cancer	1.66e-06	0.00096	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CA9—kidney cancer	1.63e-06	0.000942	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—LDHB—kidney cancer	1.63e-06	0.000941	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GPC3—kidney cancer	1.57e-06	0.000909	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CA2—kidney cancer	1.53e-06	0.000884	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ALAD—kidney cancer	1.49e-06	0.000861	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ST3GAL2—kidney cancer	1.46e-06	0.000841	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PDHB—kidney cancer	1.44e-06	0.000834	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—POMC—kidney cancer	1.44e-06	0.000831	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ALDH1A1—kidney cancer	1.42e-06	0.000822	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CA9—kidney cancer	1.41e-06	0.000816	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CRABP1—kidney cancer	1.39e-06	0.000801	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.38e-06	0.000798	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PGK1—kidney cancer	1.36e-06	0.000788	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—SLC5A3—kidney cancer	1.36e-06	0.000788	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CCBL1—kidney cancer	1.36e-06	0.000784	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—LDHB—kidney cancer	1.34e-06	0.000773	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ITPR2—kidney cancer	1.29e-06	0.000745	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CRABP1—kidney cancer	1.2e-06	0.000694	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.18e-06	0.00068	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PPAT—kidney cancer	1.18e-06	0.00068	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTT1—kidney cancer	1.18e-06	0.000679	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ACHE—kidney cancer	1.18e-06	0.000679	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CA9—kidney cancer	1.16e-06	0.00067	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ITPR2—kidney cancer	1.12e-06	0.000645	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—SCARB1—kidney cancer	1.11e-06	0.000643	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PTGS1—kidney cancer	1.1e-06	0.000636	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—APRT—kidney cancer	1.09e-06	0.000632	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—FH—kidney cancer	1.09e-06	0.000632	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PSMD7—kidney cancer	1.08e-06	0.000624	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.03e-06	0.000595	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GPC3—kidney cancer	1.03e-06	0.000594	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—BCHE—kidney cancer	1.02e-06	0.000592	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTT1—kidney cancer	1.02e-06	0.000588	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ACHE—kidney cancer	1.02e-06	0.000588	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—SLC5A5—kidney cancer	1.01e-06	0.000584	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CA2—kidney cancer	1e-06	0.000578	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CRABP1—kidney cancer	9.86e-07	0.00057	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—SLC2A1—kidney cancer	9.77e-07	0.000564	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ALAD—kidney cancer	9.75e-07	0.000563	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—SCARB1—kidney cancer	9.64e-07	0.000557	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PTGS1—kidney cancer	9.54e-07	0.000551	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ST3GAL2—kidney cancer	9.52e-07	0.00055	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PSMD7—kidney cancer	9.36e-07	0.000541	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ALDH1A1—kidney cancer	9.3e-07	0.000537	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ITPR2—kidney cancer	9.17e-07	0.00053	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PGK1—kidney cancer	8.92e-07	0.000515	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—SLC5A3—kidney cancer	8.92e-07	0.000515	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—BCHE—kidney cancer	8.87e-07	0.000512	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—SLC5A5—kidney cancer	8.76e-07	0.000506	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—LDHB—kidney cancer	8.74e-07	0.000505	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—SLC2A1—kidney cancer	8.46e-07	0.000489	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ACHE—kidney cancer	8.36e-07	0.000483	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTT1—kidney cancer	8.36e-07	0.000483	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.21e-07	0.000474	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTP1—kidney cancer	8.15e-07	0.000471	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—SCARB1—kidney cancer	7.91e-07	0.000457	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PTGS1—kidney cancer	7.83e-07	0.000452	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ABCB1—kidney cancer	7.71e-07	0.000446	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PSMD7—kidney cancer	7.68e-07	0.000444	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CA9—kidney cancer	7.58e-07	0.000438	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTM1—kidney cancer	7.49e-07	0.000433	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—BCHE—kidney cancer	7.28e-07	0.000421	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—SLC5A5—kidney cancer	7.19e-07	0.000416	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.16e-07	0.000414	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP1A1—kidney cancer	7.1e-07	0.00041	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTP1—kidney cancer	7.06e-07	0.000408	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—SLC2A1—kidney cancer	6.95e-07	0.000401	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ABCB1—kidney cancer	6.68e-07	0.000386	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTM1—kidney cancer	6.49e-07	0.000375	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CRABP1—kidney cancer	6.45e-07	0.000372	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP1A1—kidney cancer	6.15e-07	0.000355	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ITPR2—kidney cancer	5.99e-07	0.000346	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTP1—kidney cancer	5.79e-07	0.000335	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ABCB1—kidney cancer	5.48e-07	0.000317	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ACHE—kidney cancer	5.47e-07	0.000316	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTT1—kidney cancer	5.47e-07	0.000316	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTM1—kidney cancer	5.32e-07	0.000308	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—POMC—kidney cancer	5.29e-07	0.000306	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—SCARB1—kidney cancer	5.17e-07	0.000299	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PTGS1—kidney cancer	5.12e-07	0.000296	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.05e-07	0.000292	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP1A1—kidney cancer	5.05e-07	0.000292	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PSMD7—kidney cancer	5.02e-07	0.00029	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—BCHE—kidney cancer	4.76e-07	0.000275	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.7e-07	0.000272	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—POMC—kidney cancer	4.58e-07	0.000265	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.54e-07	0.000262	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PTGS2—kidney cancer	4.22e-07	0.000244	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTP1—kidney cancer	3.79e-07	0.000219	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—POMC—kidney cancer	3.76e-07	0.000217	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PTEN—kidney cancer	3.68e-07	0.000213	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PTGS2—kidney cancer	3.66e-07	0.000211	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ABCB1—kidney cancer	3.59e-07	0.000207	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTM1—kidney cancer	3.48e-07	0.000201	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.3e-07	0.000191	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PTEN—kidney cancer	3.19e-07	0.000184	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PTGS2—kidney cancer	3e-07	0.000173	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PTEN—kidney cancer	2.62e-07	0.000151	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PIK3CA—kidney cancer	2.6e-07	0.00015	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—POMC—kidney cancer	2.46e-07	0.000142	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PIK3CA—kidney cancer	2.25e-07	0.00013	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PTGS2—kidney cancer	1.96e-07	0.000113	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.85e-07	0.000107	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PTEN—kidney cancer	1.71e-07	9.89e-05	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.21e-07	6.98e-05	CbGpPWpGaD
